Report of NE CEPAC Meeting

Recently, The Pink Sheet (subscription only) included an analysis of a roundtable discussion convened by the Institute for Clinical and Economic Review (ICER) to discuss ICER’s report on the rheumatoid arthritis market. Dr. Andrew Laster represented United Rheumatology at that meeting. In the article’s discussion of the increasingly prevalent requirement for step-therapy before treatment for most biologics is covered by insurers, Dr. Laster states, “We’re concerned that going with [one or two tumor necrosis factor inhibitors as] the only thing you can start with and you have to walk through doesn’t seem appropriate based on the guidelines and based on the [cost effectiveness] data [ICER] has brought.” Dr. Laster has provided UR members a summary of discussions at the ICER meeting which can be accessed below.
[embeddoc url=””]

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.


Find a UR Rheumatologist Near Me

© 2023 United Rheumatology